AIM joint venture

AIM (Advanced Inhalation Medicine) is a strategic joint venture established between AstraZeneca, Ionis Pharmaceuticals, and MedImmune to develop novel inhaled therapies for respiratory diseases. The collaboration leverages Ionis's antisense technology and AstraZeneca's expertise in respiratory medicine to create targeted treatments for conditions such as asthma and chronic obstructive pulmonary disease (COPD). By focusing on the delivery of antisense oligonucleotides directly to the lungs, the venture aims to modulate disease-driving proteins with high precision. The partnership represents a significant effort to advance the next generation of inhaled genetic medicines.